NCT03122262View on ClinicalTrials.gov

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

1,110

Participants

Timeline

Start Date

January 16, 2017

Primary Completion Date

April 30, 2022

Study Completion Date

July 29, 2022

Conditions

HIV-1 Infection

Interventions

DRUG

Dolutegravir

DTG 50mg Oral Tablet once daily

DRUG

Tenofovir Alafenamide

TAF/FTC 25/200mg Oral Tablet once daily

DRUG

Truvada

DRUG

Atripla

Trial Locations (4)

2001

Shandukani Research Centre, Johannesburg

2196

Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg

Unknown

Sunnyside Office Park, Johannesburg

Wits RHI Yeoville Clinic, Johannesburg

All Listed Sponsors

lead

Professor Francois Venter

OTHER

NCT03122262 - ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy | Biotech Hunter | Biotech Hunter